Anke van Engen

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials

Dony Patel, Fiona Grimson, Elena Mihaylova et al. · Value in Health · 2021 · 73 citations · Full text

Medicine, Oncology, Drug Approval Processes +7

Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany

Matthias Augustin, Marc Alexander Radtke, Anke van Engen et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2009 · 18 citations

Pharmacy, Dermatology, Pharmacoeconomics +13

The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment

Anke van Engen, Robert Krüger, Adam Parnaby et al. · Value in Health · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacoeconomics +14

De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic<i>Candida</i>infections

R.G. Masterton, Montserrat Casamayor, Primrose Musingarimi et al. · Journal of Medical Economics · 2013 · 10 citations

Life Sciences, Infectious Diseases, Microbiology +17